stock market news, parkinson s disease therapeutic market revenue is ex 5013497999332112

INO - Inovio Pharmaceuticals Stock Trading

Inovio Pharmaceuticals Inc.(NASDAQ: INO) stock trading, description, contact, officers and directors.

About Inovio Pharmaceuticals Inc.

The achievements of stimulating the immune system through vaccination have been profound. INO s synthetic vaccines are designed to treat as well as prevent illnesses, aiming to break the body s tolerance of cancerous cells and protect against diverse while changing strains of infectious diseases. INO s SynCon vaccines are designed to provide universal cross strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio s proprietary electroporation delivery, have been shown in humans to generate best in class immune responses with a favorable safety profile.

Stock Information

Inovio Pharmaceuticals Inc. Company Name:

INO Stock Symbol:

NASDAQ Market:

Inovio Pharmaceuticals Inc. Website:

INO - Inovio Pharmaceuticals Stock Trading

INO INO Quote INO Short INO News INO Articles INO Message Board

Get INO Alerts

News, Short Squeeze, Breakout and More Instantly...

INO - Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q1 2021 Earnings Call May 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript
INO - INOVIO Reports First Quarter 2021 Financial Results

INOVIO Reports First Quarter 2021 Financial Results Investor Call Today at 4:30 PM ET PR Newswire PLYMOUTH MEETING, Pa. , May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed D...
INO - INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segm...